EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms

Olga Ivanova iD, Tatiana Karelina iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Olga Ivanova und 1 weiteren Autor:innen. Beteiligte Einrichtung: InSysBio CY, Limassol, Cyprus. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main pathophysiological hallmark of Parkinson's disease (PD) is the accumulation of aggregated alpha‐synuclein (αSyn). Microglial activation is an early event in PD and may play a key role in pathological αSyn aggregation and transmission, as well as in clearance of αSyn and immunotherapy efficacy. Our aim was to investigate how different proposed mechanisms of anti‐αSyn immunotherapy may contribute to pathology reduction in various PD‐like mouse models. Our mechanistic model of PD pathology in mouse includes αSyn production, aggregation, degradation and distribution in neurons, secretion into interstitial fluid, internalization, and subsequent clearance by neurons and microglia. It describes the influence of neuroinflammation on PD pathogenesis and dopaminergic neurodegeneration. Multiple data from mouse PD models were used for calibration and validation. Simulations of anti‐αSyn passive immunotherapy adequately reproduce preclinical data and suggest that (1) immunotherapy is efficient in the reduction of aggregated αSyn in various models of PD‐like pathology; (2) prevention of aSyn spread only does not reduce the pathology; (3) a decrease in microglial inflammatory activation and aSyn aggregation may be alternative therapy approaches in PD‐like pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinParkinson DiseaseDisease Models, AnimalAnimalsMiceMicrogliaNetwork PharmacologyImmunization, PassiveHumans

Substanzen

alpha-Synuclein

Autor:innen und Institutionen

  • InSysBio CY, Limassol, Cyprus.

ORCID-Profile: Olga Ivanova, Tatiana Karelina

Zitieren

APA

Ivanova, O., & Karelina, T. (2024). Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13223

Vancouver

Ivanova O, Karelina T. Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13223

BibTeX
@article{Ivanova2024,
  author = {Ivanova, Olga and Karelina, Tatiana},
  title = {Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13223}
}
Kostenlos starten →